Global biotech company Incyte (INCY) announced on Friday that it has initiated a Phase 3 clinical trial in collaboration with Novartis (NVS) to test the potential of its Jakavi drug in patients infected with the coronavirus-caused COVID-19.Jakavi is used in adults with bone marrow cancer, or myelofibrosis, among other conditions. Incyte and Novartis seek to evaluate if the drug helps COVID-19 patients suffering from an immune system overreaction, also called a cytokine storm, which could result in complications like pneumonia or acute respiratory distress syndrome. The Phase 3 study will compromise about 400 patients globally. The collaborative study will be …read more
Source:: Yahoo Finance
